O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 1996

Primary Completion Date

July 31, 2000

Study Completion Date

February 29, 2004

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

O6-benzylguanine

Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

DRUG

carmustine

After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

DRUG

chemosensitization/potentiation therapy

Trial Locations (2)

44106

Veterans Affairs Medical Center - Cleveland, Cleveland

44106-5065

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00002604 - O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter